home / stock / ruby / ruby news

RUBY News and Press, Rubius Therapeutics Inc. From 04/11/22

Stock Information
Company Name: Rubius Therapeutics Inc.
Stock Symbol: RUBY
Market: OTC
Website: rubiustx.com
Menu
RUBY RUBY Quote RUBY Short RUBY News RUBY Articles RUBY Message Board
Get RUBY Alerts

News, Short Squeeze, Breakout and More Instantly...
RUBY - CTRM, VIRX and CYTO among mid-day movers

Gainers: Veru (VERU) +196%. Hoth Therapeutics (HOTH) +126%. Altamira Therapeutics (CYTO) +54%. Iveda Solutions (IVDA) +37%. VNET Group (VNET) +30%. SailPoint Technologies Holdings (SAIL) +29%. Castor Maritime (CTRM) +25%. Datto Holding (MSP) +21%. Axcella Health (AXLA) +16%. TScan Therapeutic...
RUBY - Rubius Therapeutics falls 45% after updated early-stage data on solid tumors candidate

Shares of Rubius Therapuetics (NASDAQ:RUBY) tumbled 45% Friday after the company released updated phase 1/2 data on RTX-240 for advanced solid tumors. Partial responses were seen in some patients with non-small cell lung cancer ("NSCLC"), metastatic anal cancer, and metastatic ...

RUBY - Rubius Therapeutics Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors Demonstrating Single-Agent Activity and Favorable Tolerability

Best Responses Include Partial Responses in Certain Patients with Non-Small Cell Lung Cancer, Metastatic Anal Cancer and Metastatic Uveal Melanoma with No Treatment-Related Grade 3/4 Adverse Events or Dose-Limiting Toxicities as of the Cutoff Date Expanding Ongoing Phase 1 Arm of RTX-...

RUBY - EPAM, MULN and BORR among mid-day movers

Gainers: MedAvail (MDVL) +72%. Lyra Therapeutics (LYRA) +31%. TSR (TSRI) +24%. Biofrontera (BFRI) +18%. Takung Art (TKAT) +16%. Akanda (AKAN) +15%. Mullen Automotive (MULN) +16%. Nurix Therapeutics (NRIX) +14%. Borr Drilling (BORR) +14%. EPAM Systems (EPAM) +13%. Losers: Kaleid...
RUBY - Rubius Therapeutics to Host Investor Webcast to Discuss Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Patients with Advanced Solid Tumors on April 8, 2022, at 1:15 PM ET

CAMBRIDGE, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treat...

RUBY - Rubius Looks Attractive Before AACR Data Readout

Last year's AACR data saw impressive movement for the stock. This year, expectations are somewhat numbed. However, I still expect some small spike. For further details see: Rubius Looks Attractive Before AACR Data Readout

RUBY - Rubius Therapeutics to Present Updated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 at the American Association of Cancer Research Annual Meeting

Updated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 in Advanced Solid Tumors to be Presented in a Poster at the American Association of Cancer Research Annual Meeting on Tuesday, April 12, 2022, from 9:00 a.m. – 12:30 p.m. ET Management to Host Investor Webcast to...
RUBY - RUBY, MASS and ROVR among after hour movers

Gainers: Rubius Therapeutics (NASDAQ:RUBY) +13%. Clarus Corporation (NASDAQ:CLAR) +10%. 908 Devices  (NASDAQ:MASS) +6%. Velodyne Lidar (NASDAQ:VLDR) +3%. Golar LNG Limited (NASDAQ:GLNG) +3%. Losers: Rover Group (NASDAQ:ROVR) -13%. ThredUp  (NASDAQ:TDUP) -10%. Immersio...

RUBY - Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs

Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs PR Newswire CAMBRIDGE, Mass. , Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology a...

RUBY - Rubius Therapeutics GAAP EPS of -$0.61 misses by $0.02

Rubius Therapeutics press release (NASDAQ:RUBY): Q4 GAAP EPS of -$0.61 misses by $0.02. As of December 31, 2021, cash and cash equivalents were $225.8M as compared to $176.3M in cash, cash equivalents and investments as of December 31, 2020, For further details see: Rubius Therapeutics ...
Previous 10 Next 10